Huang Ju, Li Geng, Zhang Xiao-Xiao, Ma Yong, Zhan Zhi-Lai, Yuan Wei-An, Qu Li-Ping, Huang Shi-Yao, Li Bo, Yan Bo-Hua, Li Wen-Yuan, Liu Li, Wang Zhi-Lei, Feng Yi, Zhang Lei, Tang Jian-Yuan
Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610032, China.
Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing 100193, China.
Zhongguo Zhong Yao Za Zhi. 2022 Sep;47(17):4799-4813. doi: 10.19540/j.cnki.cjcmm.20220527.501.
Since the 18th National Congress of the Communist Party of China(CPC), the CPC and the government have highligh-ted the development of traditional Chinese Medicine(TCM) and issued a series of policies, such as the Plan for Protection and Deve-lopment of Chinese Medicinal Materials(2015-2020) forwarded by the General Office of the State Council in 2015, the Plan for Healthy Development of Traditional Chinese Medicine(2015-2020) released by the General Office of the State Council in the same year, the Healthy China 2030 Plan published by the CPC Central Committee and the State Council in 2016, the Law of the People's Republic of China on Traditional Chinese Medicine which took effect on July 2017, On the Preservation and Innovative Development of Traditional Chinese Medicine promulgated by CPC Central Committee and the State Council in 2019, and Plan for the Development of Traditional Chinese Medicine during the 14th Five-Year Plan Period of China released by the General Office of the State Council in March 2022, to promote the development of the TCM industry, which have brought historical opportunities to the TCM industry. However, TCM industry faces various challenges in the development. In terms of drug development in TCM, the current studies mainly focused on the chemical research and technical requests, which neglected TCM characteristics and cased in conformity between new drug transformation of TCM and clinical practice. Therefore, a more considerable and profound authoritative guideline is needed, and innovative thought and research are necessary for academics and the industry. Through the investigation of the development TCM industry in recent years, this study summarized the policies on and trends of Chinese medicinal materials, new drug development in TCM, catalogue of national basic drugs, and national basic health insurance, and proposed suggestions for further development of TCM industry.
党的十八大以来，党和政府高度重视中医药发展，出台了一系列政策，如2015年国务院办公厅转发的《中药材保护和发展规划（2015—2020年）》、同年国务院办公厅发布的《中医药健康服务发展规划（2015—2020年）》、2016年中共中央、国务院印发的《“健康中国2030”规划纲要》、2017年7月施行的《中华人民共和国中医药法》、2019年中共中央、国务院印发的《关于促进中医药传承创新发展的意见》以及2022年3月国务院办公厅发布的《“十四五”中医药发展规划》等，推动中医药产业发展，给中医药产业带来了历史性机遇。然而，中医药产业在发展中面临着诸多挑战。在中药研发方面，目前的研究主要集中在化学研究和技术要求上，忽视了中医药特色，导致中药新药转化与临床实践脱节。因此，需要更具分量和深度的权威性指导意见，学术界和产业界都需要创新思维和研究。通过对近年来中医药产业发展情况的调研，本研究总结了中药材、中药新药研发、国家基本药物目录、国家基本医疗保险等方面的政策及发展趋势，并对中医药产业的进一步发展提出了建议。
